New drug combo aims to tackle tough lymphoma
NCT ID NCT06453044
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing a combination of two targeted drugs, mosunetuzumab and polatuzumab vedotin, in about 41 adults with follicular lymphoma that has relapsed or is refractory. The drugs work by helping the immune system attack cancer cells and delivering a toxic agent directly to them. The main goals are to see how safe the combination is and how many patients achieve a complete response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mosunetuzumab and polatuzumab vedotin
- What this could lead to
- If this works, it could offer a new treatment option for people with follicular lymphoma that has returned or not responded to prior therapy.
- What could go wrong
- This is an early phase 2 trial with only 41 participants, so results may not apply to everyone. Side effects like cytokine release syndrome are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GRADE 1 FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
-
City of Hope Orange County Lennar Foundation Cancer Center
NOT_YET_RECRUITINGIrvine, California, 92618, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- Engineered immune cells target lymphoma after transplant
- New trial aims to bring targeted lymphoma drugs to minority patients
- New Two-Step transplant shows promise for blood cancer patients
- New strategy aims to tame common virus after stem cell transplants
- New drug combo aims to tackle tough lymphoma